The future outlook for Avacta Group relies heavily on the clinical progression and commercial validation of its proprietary preCISION tumor-targeted chemotherapy platform and Affimer therapeutics. Success in advancing clinical pipelines toward regulatory approvals, forming strategic biopharma licensing partnerships, and optimizing capital efficiency will dictate its medium-to-long-term equity performance.